Dexamethasone phosphate disodium (Dexamethasone 21-phosphate disodium salt)
(Synonyms: 地塞米松磷酸二钠; Dexamethasone 21-phosphate disodium salt) 目录号 : GC31658
A glucocorticoid
Cas No.:2392-39-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Dexamethasone phosphate is a glucocorticoid.1 It reduces LPS-induced production of RANTES, TGF-β1, and nitric oxide (NO) in BV-2 microglia when used at concentrations ranging from 1 to 4 ?M. Dexamethasone phosphate reverses LPS-induced decreases in IL-10 levels in, and inhibits LPS-induced migration of, BV-2 microglia when used at a concentration of 4 ?M. In vivo, dexamethasone phosphate decreases motor activity and reduces adrenal weight and plasma corticosterone levels in rats when administered in the drinking water at a concentration of 5 ?g/ml.2 Dexamethasone phosphate (1.6 mg/kg per day) reduces joint swelling in a rat model of collagen-induced arthritis when administered for a minimum of seven days.3 It also reduces pruritis and the clinical lesion score in cats with hypersensitivity dermatitis.4 Formulations containing dexamethasone phosphate have been used in the treatment of various inflammatory diseases, arthritis, and endocrine disorders.
1.Hui, B., Yao, X., Zhang, L., et al.Dexamethasone sodium phosphate attenuates lipopolysaccharide-induced neuroinflammation in microglia BV2 cellsNaunyn Schmiedebergs Arch. Pharmacol.393(9)1761-1768(2020) 2.Katz, R.J., and Carroll, B.J.Endocrine control of psychomotor activity in the rat: Effects of chronic dexamethasone upon general activityPhysiol. Behav.20(1)25-30(1978) 3.Rauchhaus, U., Schwaiger, F.W., and Panzner, S.Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: Long-term suppression of arthritis facilitates interval treatmentArthritis Res. Ther.11(6)R190(2009) 4.McClintock, D., Austel, M., Gogal, R.M., Jr., et al.Oral dexamethasone sodium phosphate solution significantly reduces pruritus and clinical lesions in feline hypersensitivity dermatitis: An open-label studyVet. Dermatol.32(5)497-e137(2021)
|
Animal experiment: |
Rats: Male Sprague-Dawley rats are used. Dexamethasone-treated rats are injected intraperitoneally once daily with Dexamethasone (1.5 mg/kg body weight) for 5 days and are allowed to feed ad libitum. Control rats receive no treatment and are fed ad libitum. In order to take into account the decrease in food intake induced by Dexamethasone treatment, a third group of pair-fed rats are used. These rats are provided with the same amount of food as Dexamethasone-injected rats and are treated with a daily isovolumic intraperitoneal injection of NaCl (0.9%) for 5 days. After the final injection of Dexamethasone or NaCl, the animals are fasted overnight prior to being killed by decapitation[4].Mice: Female C57Bl/6JBom mice (age 10-12 weeks) are used in all experiments. Dexamethasone is administered as a single injection of 1 or 10 mg/kg. Dexamethasone is dissolved in saline and 400 μL are injected intraperitoneally, either 1 h before or 1 h after LPS exposure. In one experiment, N-acetylcysteine (NAC) (100 and 500 mg/kg) is injected successively every 4-5 h, starting 1 h before challenge (five injections in total). A control group of LPS-exposed animals are injected intraperitoneally with solvent alone (saline). Intratracheal administration is performed by instillation of 100 μL NAC (50, 100 or 500 mg/kg) or Dexamethasone (10 mg/kg) into the lungs of mice anaesthetized with 15 mg/kg Rapinovet (i.v.)[3]. |
|
References: [1]. LaLone CA, et al. Effects of a glucocorticoid receptor agonist, Dexamethasone, on fathead minnow reproduction, growth, and development. Environ Toxicol Chem. 2012 Mar;31(3):611-22. |
|
| Cas No. | 2392-39-4 | SDF | |
| 别名 | 地塞米松磷酸二钠; Dexamethasone 21-phosphate disodium salt | ||
| Canonical SMILES | O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@]4(O)C(COP([O-])([O-])=O)=O)=C1.[Na+].[Na+] | ||
| 分子式 | C22H28FNa2O8P | 分子量 | 516.4 |
| 溶解度 | Water : ≥ 106.67 mg/mL (206.56 mM) | 储存条件 | Store at -20°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9365 mL | 9.6824 mL | 19.3648 mL |
| 5 mM | 0.3873 mL | 1.9365 mL | 3.873 mL |
| 10 mM | 0.1936 mL | 0.9682 mL | 1.9365 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet